Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial

Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial

Abstract Background The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure (ARF) are controversial, with two large triple-blind RCTs reaching very important difference in the effe...

Full description

Bibliographic Details
Main Authors: Sylvie Chevret, Lila Bouadma, Claire Dupuis, Charles Burdet, Jean-François Timsit, the COVIDICUS RCT group
Format: Article
Language:English
Published: SpringerOpen 2023-08-01
Series:Annals of Intensive Care
Subjects:
SARS-Cov-2
Steroids
Dose
Sepsis
Acute respiratory failure
Remdesivir
Online Access:https://doi.org/10.1186/s13613-023-01168-z

Internet

https://doi.org/10.1186/s13613-023-01168-z

Similar Items